A5060873943- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- SARS-CoV-2 and COVID-19 Research
- Immune Cell Function and Interaction
- COVID-19 Clinical Research Studies
- vaccines and immunoinformatics approaches
- CAR-T cell therapy research
- RNA Interference and Gene Delivery
- Dermatology and Skin Diseases
- Immune responses and vaccinations
- IL-33, ST2, and ILC Pathways
- Monoclonal and Polyclonal Antibodies Research
- SARS-CoV-2 detection and testing
- Nanoplatforms for cancer theranostics
- DNA and Nucleic Acid Chemistry
- Toxin Mechanisms and Immunotoxins
- Prostate Cancer Treatment and Research
- Cancer Research and Treatments
- Hematopoietic Stem Cell Transplantation
- Glioma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Advanced biosensing and bioanalysis techniques
- Animal Virus Infections Studies
- Bacillus and Francisella bacterial research
- T-cell and B-cell Immunology
BioNTech (Germany)
2015-2024
Goethe University Frankfurt
2008-2023
Ribocon (Germany)
2014
Georg Speyer Haus
2010
Omicron is the evolutionarily most distinct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern (VOC) to date. We report that BA.1 breakthrough infection in BNT162b2-vaccinated individuals resulted strong neutralizing activity against BA.1, BA.2, and previous SARS-CoV-2 VOCs but not sublineages BA.4 BA.5. induced a robust recall response, primarily expanding memory B (B
BNT162b2, a lipid nanoparticle (LNP) formulated nucleoside-modified messenger RNA (mRNA) encoding the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S) stabilized in prefusion conformation, has demonstrated 95% efficacy to prevent disease 2019 (COVID-19). Recently, we reported preliminary BNT162b2 safety and antibody response data from an ongoing placebo-controlled, observer-blinded phase 1/2 vaccine trial 1 . We present here T cell responses second,...
Evolution of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant has led to emergence sublineages with different patterns neutralizing antibody evasion. We report that BA.4/BA.5 breakthrough infection individuals immunized SARS-CoV-2 wild-type-strain-based mRNA vaccines results in a boost BA.4.6, BF.7, BQ.1.1, and BA.2.75 neutralization but does not efficiently BA.2.75.2, XBB, or XBB.1.5 neutralization. In silico analyses showed spike glycoprotein lost most B...
An effective vaccine is needed to halt the spread of SARS-CoV-2 pandemic. Recently, we reported safety, tolerability and antibody response data from an ongoing placebo-controlled, observer-blinded phase 1/2 COVID-19 trial with BNT162b1, a lipid nanoparticle (LNP) formulated nucleoside-modified messenger RNA encoding receptor binding domain (RBD) spike protein. Here present T cell responses after BNT162b1 vaccination second, non-randomized open-label in healthy adults, 18-55 years age. Two...
T-cell-based adoptive immunotherapy is widely used to treat graft rejection and relapse after stem cell transplantation (SCT). However, this approach hampered by a high risk of life-threatening graft-versus-host-disease (GvHD). Clinical trials have demonstrated the value suicide genes modify T cells for effective control GvHD. Herewith, we show that combination codon-optimized B-cell antigen (CD20op) with selection marker based on cytoplasmic truncated version human CD34 (tCD34) allows...
A Correction to this paper has been published: https://doi.org/10.1038/s41586-020-03102-w
<h3>Background</h3> PRO-MERIT is a FIH, open-label, multicenter, Phase I/IIa trial investigating liposomal RNA vaccine (BNT112) targeting the prostate cancer tumor-associated antigens (TAAs) kallikrein-2, kallikrein-3, acid phosphatase prostate, homeobox B13 (HOXB13), and NK3 1. BNT112 being investigated as monotherapy in combination with cemiplimab patients metastatic castration-resistant (mCRPC) newly diagnosed high risk localized (LPC). <h3>Methods</h3> The involves dose titration mCRPC...
3136 Background: Cancer vaccines are considered unsuitable for patients with advanced tumours and have not been clinically successful. Methods: Lipo-MERIT is an ongoing phase 1/2 trial (NCT02410733) melanoma FixVac, a liposomal RNA vaccine targeting four non-mutant shared tumour-associated antigens (TAAs) (MAGE-A3, NY-ESO-1, tyrosinase, TPTE). Patients stage IIIB-C IV eligible. The comprises 7 dose escalation 3 expansion cohorts, the latter FixVac alone or combined anti-PD1. Eight doses of...
Abstract Omicron is the evolutionarily most distinct SARS-CoV-2 variant (VOC) to date and displays multiple amino acid alterations located in neutralizing antibody sites of spike (S) protein. We report here that breakthrough infection BNT162b2 vaccinated individuals results strong activity not only against Omicron, but also broadly previous VOCs SARS-CoV-1. found mediates a robust B cell recall response, primarily expands preformed memory cells recognize epitopes shared by different...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposure histories become increasingly complex through original and variant-adapted vaccines infections with viral variants. Upon to the highly altered Omicron spike glycoprotein, pre-immunized individuals predominantly mount recall responses of Wuhan-Hu-1 (wild-type)-imprinted memory B (BMEM) cells mostly targeting conserved non-neutralizing epitopes, leading diminished neutralization. We investigated impact imprinting in...
Keratinocyte-associated C-type lectin (KACL) is a peculiar lectin-like receptor (CTLR) due to its selective expression by human keratinocytes and cognate interaction with the genetically coupled CTLR NKp65. KACL NKp65 are members of CLEC2 NKRP1 subfamilies natural killer gene complex (NKC)-encoded CTLR, respectively. Most molecules expressed on NK cells T act as receptors glycoproteins their genes being intermingled in certain sub-region mammalian NKC. The reasons for tight genetic linkage...
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related deaths worldwide due to high recurrence rates after curative treatment and being frequently diagnosed at an advanced stage. Immune-checkpoint inhibition (ICPI) has yielded impressive clinical successes in a variety solid cancers, however results HCC have been modest. Vaccination could be promising synergize with ICPI enhance response rates. Cancer testis antigens (CTAs) were recently discovered widely expressed...
<h3>Background</h3> Lipo-MERIT is an ongoing, first-in-human, open-label, dose-escalation Phase I trial investigating safety, tolerability and immunogenicity of BNT111 in patients with advanced melanoma. RNA-LPX vaccine targeting the melanoma tumor-associated antigens (TAAs) New York esophageal squamous cell carcinoma 1 (NY-ESO-1), tyrosinase, melanoma-associated antigen 3 (MAGE-A3), transmembrane phosphatase tensin homology (TPTE). A previous exploratory interim analysis showed that BNT111,...
Abstract Cancer arises from the accumulation of genomic alterations and epigenetic changes that constitute a hallmark cancer. Owing to molecular heterogeneity in cancer, only minor fraction patients profit approved therapies. Available targeted therapies can address common particular type cancer induce transient effects due generation resistant sub-clones. In contrast, IVAC MUTANOME project aims immunologically target multiple mutations uniquely expressed given patient's tumor. The approach...
Abstract NKp80 is an activating C-type lectin-like immunoreceptor (CTLR) on human NK cells. Upon ligation by its cognate ligand ‘activation-induced lectin’ (AICL) up-regulated PAMP-stimulated myeloid cells and interleukin-experienced cells, stimulates cytotoxicity cytokine secretion. Unlike other receptors, uses atypical cytoplasmic hemITAM for cellular activation. In contrast to “classical” hemITAMs of related CTLR, we showed that the does not recruit Syk upon phosphorylation. However, now...
Innate lymphocytes comprise cytotoxic natural killer (NK) cells and tissue-resident innate lymphoid (ILC) that are subgrouped according to their cytokine profiles into group 1 ILC (ILC1), ILC2, ILC3. However, cell surface receptors unambiguously defining or specifically activating such subsets scarcely known. Here, we report on the physiologic expression of human C-type lectin-like receptor (CTLR) NKp65, a high-affinity for CTLR keratinocyte-associated lectin (KACL). Tracking rare NKp65...
Abstract One of the hallmarks cancer is inherent instability genome leading to multiple genomic alterations and epigenetic changes that ultimately drive carcinogenesis. These processes lead a unique molecular profile every given tumor substantial intratumoral heterogeneity tissues. Recently, series independent reports revealed pre-formed neoantigen specific T-cell responses are crucial relevance for clinical efficacy immune checkpoint inhibitors. However, spontaneous recognition neoantigens...